Last Updated: May 11, 2026

Details for Patent: 11,312,698

Name: Drug Patent Intelligence for US Patent 11312698
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,312,698 protect, and when does it expire?

Patent 11,312,698 protects AKYNZEO and is included in one NDA.

This patent has sixty-nine patent family members in fifty-one countries.

Summary for Patent: 11,312,698

Title:	Fosnetupitant chloride hydrochloride having improved stability
Abstract:	Fosnetupitant chloride hydrochloride having improved stability, characterized by the following chemical structure:
Inventor(s):	Luca Fadini, Peter Manini, Claudio Pietra, Claudio Giuliano, Emanuela Lovati, Roberta Cannella, Alessio Venturini, Valentino J. Stella
Assignee:	Helsinn Healthcare SA
Application Number:	US16/896,135
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,312,698
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 11,312,698

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Helsinn Hlthcare	AKYNZEO	fosnetupitant chloride hydrochloride; palonosetron hydrochloride	POWDER;INTRAVENOUS	210493-001	Apr 19, 2018		DISCN	Yes	No	11,312,698	⤷ Start Trial	Y	Y			⤷ Start Trial
Helsinn Hlthcare	AKYNZEO	fosnetupitant chloride hydrochloride; palonosetron hydrochloride	SOLUTION;INTRAVENOUS	210493-002	May 27, 2020		RX	Yes	Yes	11,312,698	⤷ Start Trial	Y	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,312,698

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2785706	⤷ Start Trial	301047	Netherlands	⤷ Start Trial
European Patent Office	2785706	⤷ Start Trial	CA 2020 00028	Denmark	⤷ Start Trial
European Patent Office	2785706	⤷ Start Trial	PA2020510	Lithuania	⤷ Start Trial
European Patent Office	2785706	⤷ Start Trial	LUC00158	Luxembourg	⤷ Start Trial
European Patent Office	2785706	⤷ Start Trial	2020C/516	Belgium	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.